Skip to main content

Table 1 Patients’ characteristics

From: Survival in endometrial cancer in relation to minimally invasive surgery or open surgery – a Swedish Gynecologic Cancer Group (SweGCG) study

Variable

MIS

N = 3742

Open surgery

N = 3533

Total

N = 7275

p

Age, mean (min-max)

68.6 (25–98)

68.5 (29–97)

68.5 (25–98)

0.93a

Age, median (25–75%)

69 (62–76)

69 (62–76)

69 (62–76)

0.78b

Age, years

   

0.95c

 0–59

718 (19.2%)

696 (19.7%)

1414 (19.4%)

 

 60–69

1185 (31.7%)

1110 (31.4%)

2295 (31.6%)

 

 70–79

1261 (33.7%)

1190 (33.7%)

2451 (33.7%)

 

  ≥ 80

578 (15.4%)

572 (15.2%)

1115 (15.3%)

 

WHO performance status

   

0.002d

 0

2230 (59.6%)

1453 (41.1%)

3683 (50.6%)

 

 1

789 (21.1%)

634 (18.0%)

1423 (19.6%)

 

 2

175 (4.7%)

127 (3.6%)

302 (4.2%)

 

 3

20 (0.5%)

23 (0.6%)

43 (0.6%)

 

 4

2 (0.0%)

5 (0.1%)

7 (0.1%)

 

 Missing

526 (14.1%)

1291 (36.5%)

1817 (25.0%)

 

FIGO stage

   

< 0.001c

 IA

2481 (66.3%)

1925 (54.5%)

4406 (60.6%)

 

 IB

744 (19.9%)

783 (22.2%)

1527 (21.0%)

 

 II

249 (6.6%)

315 (8.9%)

564 (7.8%)

 

 III

268 (7.2%)

510 (14.4%)

778 (10.7%)

 

Morphology

   

< 0.001c

 Endometrioid

3426 (91.6%)

2960 (83.8%)

6386 (87.8%)

 

 FIGO grade 1–2

2976 (86.9%)

2281 (77.1%)

5257 (82.3%)

 

 FIGO grade 3

362 (10.6%)

573 (19.4%)

935 (14.6%)

 

 Missing

88 (2.6%)

106 (3.6%)

194 (3.0%)

 

Serous

196 (5.2%)

299 (8.5%)

495 (6.8%)

 

Clear cell

67 (1.8%)

108 (3.1%)

175 (2.4%)

 

Carcinosarcoma

53 (1.4%)

166 (4.7%)

219 (3.0%)

 

Postoperative risk groups

   

< 0.001c

 Low

2299 (61.4%)

1642 (46.5%)

3941 (54.2%)

 

 High

1443 (38.6%)

1891 (53.5%)

3334 (45.8%)

 

LVSI

   

< 0.001c

 No

2547 (68.1%)

2051 (58.0%)

4598 (63.2%)

 

 Yes

464 (12.4%)

646 (18.3%)

1110 (15.3%)

 

 Missing

731 (19.5%)

836 (23.7%)

1567 (21.5%)

 

Ploidy

   

< 0.001c

 Diploid

2414 (64.5%)

2005 (56.8%)

4419 (60.7%)

 

 Non-diploid

719 (19.2%)

947 (26.8%)

1666 (22.9%)

 

 Missing

609 (16.3%)

581 (16.4%)

1190 (16.4%)

 

Follow-up (years), median (25–75%)

 Censored

3.7 (2.0–5.4)

5.1 (3.2–7.1)

4.3 (2.4–6.1)

 

 Death

2.3 (1.4–3.8)

2.6 (1.3–4.3)

2.5 (1.3–4.1)

 

 All

3.5 (1.9–5.2)

4.6 (2.6–6.6)

4.0 (2.2–5.9)

 
  1. FIGO International Federtion of Gynecology and Obstetics (Federation Internationale de Gynecologie et d’Obstetrique)
  2. LVSI Lymphovascular space involvement
  3. aStudent’s t-test
  4. bWilcoxon rank-sum test
  5. cPearson’s chi-squared test
  6. dFisher’s exact test
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us